Edition:
United States

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.14USD
4:00pm EDT
Change (% chg)

$-0.04 (-1.26%)
Prev Close
$3.18
Open
$3.18
Day's High
$3.22
Day's Low
$3.12
Volume
222,402
Avg. Vol
336,955
52-wk High
$3.65
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Amarin reaches the onset of about 80 pct of the target aggregate number within the reduce-it study
Thursday, 16 Mar 2017 05:00am EDT 

Amarin Corporation Plc - : Amarin reaches the onset of approximately 80% of the target aggregate number of primary major adverse cardiovascular events within the reduce-it study . Currently expects independent interim analysis to be conducted before end of third calendar quarter of this year .Amarin says will remain blinded to interim and ongoing results of reduce-it study until ready to be stopped at interim or final analysis.  Full Article

Amarin Corp files for potential mixed shelf - SEC filing
Wednesday, 1 Mar 2017 05:24pm EST 

Amarin Corporation Plc :Amarin Corporation Plc files for potential mixed shelf; size not disclosed - sec filing.  Full Article

Amarin files for resale by the selling shareholders' of up to 10.4 mln shares- SEC filing
Wednesday, 1 Mar 2017 05:22pm EST 

Amarin Corporation Plc :Amarin Corp Plc files for resale by the selling shareholders of up to 10.4 million American Depositary Shares - SEC filing.  Full Article

Amarin reports posts Q4 loss per share $0.10
Tuesday, 28 Feb 2017 06:00am EST 

Amarin Corporation Plc : Amarin reports record fourth quarter and full year 2016 financial results and provides update on operations . Q4 loss per share $0.10 . Q4 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Qtrly total revenue, net $38.7 million versus $26.6 million .In 2017, Amarin anticipates spending approximately $50 million to $60 million for research and development.  Full Article

Amarin Corp prices public offering at $2.85 per ADS
Thursday, 11 Aug 2016 09:20am EDT 

Amarin Corporation Plc : Amarin prices public offering of american depositary shares . Pricing of underwritten public offering of 21.1 million American depositary shares at a price to public of $2.85 per ADS .Sees using net proceeds from offering to advance its reduce-it cardiovascular outcomes trial.  Full Article

Amarin Q2 loss per share $0.07
Thursday, 4 Aug 2016 06:55am EDT 

Amarin Corporation Plc : Q2 loss per share $0.07 . Amarin reports second quarter 2016 financial results and provides update on operations . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.13, revenue view $30.0 million -- Thomson Reuters I/B/E/S . Qtrly net total revenue $33.1 million versus $17.7 million .Q2 adjusted non-gaap loss per share $0.09 excluding items.  Full Article

Amarin says FDA to amend SPA agreement for cardiovascular outcomes study
Thursday, 4 Aug 2016 05:45am EDT 

Amarin Corporation Plc : Amarin and FDA reaffirm concurrence on REDUCE-IT through special protocol assessment agreement amendment . Continues to expect that DMC's 60%, 80% interim analyses will each result in a recommendation to continue reduce-it study as planned . Amendment does not change primary endpoint or overall size of reduce-it study or company's prior guidance on timing . Final efficacy analysis anticipated in 2018 .Secondary and tertiary endpoints of reduce-it study expanded.  Full Article

Amarin appoints Michael Kalb chief financial officer
Thursday, 30 Jun 2016 07:30am EDT 

Amarin Corporation Plc : Amarin appoints Michael Kalb chief financial officer .Kalb joins Amarin from Taro Pharmaceutical Industries Ltd.  Full Article

Amarin Corporation PLC scores early victory in fish oil drug marketing lawsuit - Reuters
Thursday, 6 Aug 2015 08:00pm EDT 

Amarin Corporation PLC:Says A U.S. judge on Friday barred the U.S. Food and Drug Administration from stopping Irish drugmaker Amarin Corp from promoting its fish oil drug for off-label uses, saying the company is protected by the First Amendment - Reuters.Says the pharmaceutical industry has been watching this case because it is one of the first to raise a First Amendment argument in defense of promoting drugs for uses the FDA has not approved.Says the order by U.S. District Judge Paul Engelmayer in Manhattan means Amarin can promote its Vascepa pill to doctors for off-label use as long as it does so truthfully.Says the FDA has approved Vascepa to treat patients with very high levels of blood fats known as triglycerides that have been linked to diabetes, kidney failure and pancreatic cancer.Says the FDA has approved Vascepa to treat patients with very high levels of blood fats known as triglycerides that have been linked to diabetes, kidney failure and pancreatic cancer.Says Amarin sued the FDA in May shortly after the agency refused to approve the drug for statin patients.  Full Article

More From Around the Web

BRIEF-Amarin reaches the onset of about 80 pct of the target aggregate number within the reduce-it study

* Amarin reaches the onset of approximately 80% of the target aggregate number of primary major adverse cardiovascular events within the reduce-it study